Impact of UGT1A9 polymorphism on mycophenolic acid pharmacokinetic parameters in stable renal transplant patients

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 547-556

  Mazidi, Talia ^a   Rouini, Mohammad Reza ^a   Ghahremani, Mohammad Hossein ^a   Dashti Khavidaki, Simin ^a   Lessan Pezeshki, Mahboob ^b   Lagha Ahmadi, Farrokh ^b   Salam Zadeh, Jamshid ^c   Mandegary, Ali ^d   Gholami, Kheirollah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Mycophenolate mofetil; Polymorphism; Renal transplantation; UGT

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE 1A 9;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PLASMA CONCENTRATION-TIME CURVE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84883758751     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. th ed., Elsevier, Philadelphia (2007) 2103-2165.
2. th ed., The McGrawHill companies, Inc., United States of America (2005) 781-796.
3. th ed., Lexi-Comp Inc., Ohio (2007):1038-1041.
4. AHFS Drug Information. Maryland, American Society of Health-System Pharmacists, Inc. (2007):3770-3775.
5. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, Vilardell J, Roman A, Martorell J and Capdevila L. Mycophenolic acid plasma concentrations: infuence of comedication. Ther. Drug. Monit. (2001) 23: 35-38.
6. Jeong H and Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin. J. Am. Soc. Nephrol. (2007) 2: 184-191.
7. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E and Oellerich M. MMF Creeping Creatinine Study Group, Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther. Drug. Monit. (2001) 23: 717-721.
8. Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K and Ozono S. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol. Pharm. Bull. (2006) 29: 275-280.
9. Cattaneo D, Perico N, Gaspari F, Gotti E and Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Inter. (2002) 62: 1060-1067.
10. David-Neto E, Pereira LM, Kakehashi E, Sumita NM, Mendes ME, Castro MC, Romano P, Mattos RM, Batista VR, Nahas WC and Ianhez LE. The need of mycophenolic acid monitoring in long-term renal transplants. Clin. Transplant. (2005) 19: 19-25.
11. Knight SR and Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Trans. (2008) 85: 1675-1685.
12. de Winter BC, Mathôt RA, van Hest RM and van Gelder T. Therapeutic drug monitoring of mycophenolic acid: Does it improve patients outcome? Expert Opin. Drug Metab. Toxicol. (2007) 3: 251-261.
13. Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, Zhong MK and Lu WY. Population pharmacokinetic modeling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the infuence of polymorphism in UGT1A9. Br. J. Clin. Pharmacol. (2008) 65: 893-907.
14. Hesselink DA and Van Gelder T. Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid. Clin. Pharmacol. Ther. (2005) 78: 317-321.
15. Bernard O and Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. (2004) 32: 775-778.
16. Fisher MB, Paine M F, Strelevitz TJ and Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. (2001) 33: 273-297.
17. Girard H, Court MH, Bernard O, Fortier LCH, Villeneuve L, Qin H, Greenblatt DJ, Von Moltek LL, Perussed L and Guillemette C. Identifcation of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. (2004) 14: 501-515.
18. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, Einecke G, Waiser J, Neumayer HH and Budde K. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4: 2045-2051.
19. Kazuyuki I, Masatomo M, Shigeru S, Kagaya H, Saito M, Habuchi T and Suzuki T. Infuence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther. Drug Monit. (2007) 29: 299-304.
20. Kuypers DRJ, Naesens M, Vermeire S and Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphism T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. (2005) 78: 351-361.
21. Ahadi Barzoki M, Rouini MR, Gholami KH, Lesan Pezeshki M and Rezaei S. Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. DARU (2005) 13: 120-126.
22. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T and Suzuki T. Infuence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. (2007) 63: 279-288.
23. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Tamura T, Yamamoto N, Kunitoh H, Hamaguchi T, Yoshida T, Kubota K, Ohtsu A, Muto M, Minami H, Saijo N, Kamatani N and Sawada JI. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics. (2006) 6: 63-75.
24. Kaplan B. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: Association with clinical outcomes. Curr. Med. Res. Opin. (2006) 22: 2355-2364.
25. Hubner GI, Eismann R and Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther. Drug Monit. (1999) 21: 536-539.
26. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A and Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro fndings. Transpl. Immunol. (1997) 5: 225-232.
27. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A and Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther. Drug. Monit. (1999) 21: 35-43.
28. Kobayashi M, Saitoh H, Tadano K, Tadano K, Takahashi Y and Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associ-ated protein 2 in rats. J. Pharmacol. Exp. Ther. (2004) 309: 1029-1035.
29. Van Gelder T, Klupp J, Barten MJ, Christians U and Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug. Monit. (2001) 23: 119-128.
30. Deters M, Kirchner G, Koal T, Klaus R and Volkhard K. Infuence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther. Drug. Monit. (2005) 27: 132-138.
31. Hesselink DA, van Hest RM, Mathot RA, Van Hest RM, Mathot RAA, Bonthuis F, Weimar W, De Bruin RWF and Van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. (2005) 5: 987-994.
32. Staatz CE, Duffull SB, Kiberd B, Fraser AD and Tett SE. Population pharmacokinetics of mycophenolic acid during the frst week after transplantation. Eu. J. Clin. Pharmacol. (2005) 61: 507-516.
33. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: Dose dependent effcacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1997) 64: 1277-1282.
34. Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, Fei Y, Shen C, Zhou G, Yang W and Li H. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin. Pharmacokinet. (2007) 46: 175-185.